Prestige Consumer (PBH) | Stock Overview & Key Data
Prestige Consumer Performance Comparison
Stock Range
Today's Range
Low: $62.52
High: $63.45
on October 2, 2025
52 Week Range
Low: $61.28
High: $90.04
on September 30, 2025
on March 10, 2025
All-Time High: $90.04 on March 10, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$3.8B
EPS
4.29
P/E Ratio (TTM)
17.92
Forward P/E
16.12
P/B Ratio
2.07
PEG Ratio
16.12
Div. Yield
N/A
ROE
12.30%
Beta
0.428
Debt to Equity
56.91
Financial Highlights
Profitability
Gross Margin
57.34%
Operating Margin
34.03%
Profit Margin
18.86%
Returns and Earnings
Return on Assets (TTM)
6.50%
Return on Equity (TTM)
12.30%
EBITDA
$362.0M
Net Income (TTM)
$214.6M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$22.98
Quarterly Revenue Growth (YoY)
7.10%
Quarterly Earnings Growth (YoY)
1.40%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Prestige Consumer PBH | 3.79B Mid-cap | 0.19% | -5.50% | -21.63% | -26.96% | -19.15% | -8.70% | 26.31% | 69.11% |
| Haleon Plc - ADR HLN | 41.72B Large-cap | 1.83% | -9.02% | -13.45% | -12.60% | -5.93% | -14.37% | 45.81% | 19.84% |
| United Therapeutics UTHR | 19.33B Large-cap | 4.24% | 9.54% | 50.21% | 42.01% | 23.10% | 24.59% | 114.46% | 326.34% |
| Elanco Animal Health ELAN | 9.74B Mid-cap | 8.19% | 14.68% | 39.06% | 90.06% | 69.88% | 39.63% | 66.69% | -38.16% |
| Regencell Bioscience RGC | 7.64B Mid-cap | 6.67% | 25.68% | 55.89% | 2,504.84% | 12,323.08% | 14,581.82% | 1,845.78% | 5,667.86% |
| Alkermes plc ALKS | 5.29B Mid-cap | 15.22% | 6.33% | 7.79% | -4.26% | 8.73% | 7.90% | 41.26% | 85.41% |
Ownership & Short Interest
Insider Ownership
1.23%
Institutional Ownership
108.15%
Shares Short
2M
Short Ratio
3.44
Short % of Shares Outstanding
4.28%
Average 10-Day Volume
406K
Average 90-Day Volume
412K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is PBH's 52-week high and low?
- In the last 52 weeks, Prestige Consumer reached a high of $90.04 (on March 10, 2025) and a low of $61.28 (on September 30, 2025).
- What is the market cap and P/E ratio for PBH?
- Curious about Prestige Consumer's size and valuation? Its market capitalization stands at 3.79B. When it comes to valuation, the P/E ratio (trailing twelve months) is 17.92, and the forward P/E (looking ahead) is 16.12.
- Does PBH pay dividends? If so, what's the yield?
- As for dividends, Prestige Consumer isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Prestige Consumer's main competitors or similar companies to consider before investing?
When looking at Prestige Consumer, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Haleon Plc - ADR
HLN41.72B Healthcare Drug Manufacturers - Specialty & Generic -14.37% 45.81% United Therapeutics
UTHR19.33B Healthcare Drug Manufacturers - Specialty & Generic 24.59% 114.46% Elanco Animal Health
ELAN9.74B Healthcare Drug Manufacturers - Specialty & Generic 39.63% 66.69% Regencell Bioscience
RGC7.64B Healthcare Drug Manufacturers - Specialty & Generic 14,581.82% 1,845.78% Alkermes plc
ALKS5.29B Healthcare Drug Manufacturers - Specialty & Generic 7.90% 41.26% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Prestige Consumer Healthcare Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Prestige Consumer's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 12.30%, the Debt to Equity ratio from the most recent quarter is 56.91, and its Gross Profit Margin stands at 57.34%.
- What is the recent revenue and earnings growth for PBH?
- Looking at Prestige Consumer's growth, its revenue over the trailing twelve months (TTM) was $1B. Compared to the same quarter last year (YoY), quarterly revenue grew by 7.10%, and quarterly earnings saw a YoY growth of 1.40%.
- How much of PBH stock is held by insiders and institutions?
- Wondering who owns Prestige Consumer stock? Company insiders (like executives and directors) hold about 1.23% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 108.15%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.